Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 471
interventional 309
Observational 151
Registry 11

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 143
Biological 103
Other 22
Genetic 9
Drug|placebo 8
Procedure 4
Behavioral 3
Device 3
Biological|placebo 2
Diagnostic Test 2
Behavioral|Drug 1
Biological|Drug 1
Biological|Procedure 1
Biological|Radiation 1
Device|Drug 1
Diagnostic Test|Drug|Other 1
Dietary Supplement 1
Drug|Genetic 1
Drug|Other 1
Other|placebo 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 41
China 20
NA 11
United Kingdom 10
France 7
Spain 7
Bulgaria 6
Canada 5
Poland|United Kingdom 4
Turkey 4
India 3
Israel 3
Belgium 2
Bulgaria|Russian Federation 2
Korea, Republic of 2
Poland 2
Russian Federation 2
Sweden 2
Thailand 2
United States|Australia 2
United States|Bulgaria|Russian Federation|Switzerland|United Kingdom 2
United States|United Kingdom 2
Argentina|Brazil|Bulgaria|Chile|Colombia|Czechia|India|Ireland|Italy|Japan|Poland|Romania|Russian Federation|Sweden|Taiwan|Ukraine|United Kingdom 1
Argentina|Brazil|Bulgaria|Chile|Colombia|Czechia|Poland|Romania|Russian Federation|Ukraine 1
Armenia|Georgia|Poland|Russian Federation|South Africa 1
Australia|Austria|Canada|Czech Republic|France|Germany|Israel|Italy|Russian Federation|Spain 1
Australia|Belgium|Brazil|Canada|Colombia|Finland|Germany|Guatemala|Hungary|India|Israel|Italy|Mexico|Netherlands|Panama|Poland|Portugal|Romania|Russian Federation|Saudi Arabia|Spain|Sweden|Switzerland|United Kingdom 1
Australia|United States|United Kingdom 1
Austria 1
Austria|Bulgaria|Germany|Hungary|Poland|Romania|Slovakia|United Kingdom 1
Austria|Bulgaria|Germany|United Kingdom 1
Austria|Czechia|Greece|Hungary|Italy|Poland|United States|Russian Federation|Slovenia|United Kingdom 1
Austria|Denmark|Germany|Italy|Malaysia|South Africa|Spain|Sweden|Switzerland|Thailand|United Kingdom 1
Austria|France|Germany|Hungary|Israel|Italy|Spain|Turkey 1
Austria|France|Germany|Israel|Italy|Spain 1
Belarus|Georgia|Guatemala|Lebanon|Mexico|Ukraine 1
Belgium|United States|Australia|Finland|France|Germany|Hungary|Italy|Netherlands|New Zealand|Poland|Spain|Sweden 1
Brazil 1
Bulgaria|Austria|United States|Australia|Czechia|Germany|Hong Kong|Israel|Japan|Korea, Republic of|Lithuania|Malaysia|Netherlands|Poland|Romania|Russian Federation|Spain|Sweden|Switzerland|Taiwan|Turkey|Ukraine|United Kingdom 1
Bulgaria|Canada|Croatia|Korea, Republic of|Malaysia|Mexico|Poland|Singapore|Turkey 1
Bulgaria|Canada|United States|Argentina|Austria|Belgium|Greece|Israel|Italy|Lithuania|Netherlands|New Zealand|Norway|Poland|Romania|Spain|United Kingdom 1
Bulgaria|Czechia|Hungary|Poland 1
Bulgaria|Denmark|Greece|Italy|Norway|Poland|Spain 1
Bulgaria|Germany|Hungary|Italy|Netherlands|Poland|Russian Federation|Spain|United Kingdom 1
Bulgaria|Germany|Japan|Ukraine|United Kingdom 1
Bulgaria|Germany|Japan|United Kingdom 1
Bulgaria|Hungary|Poland|Romania|Russian Federation 1
Bulgaria|Hungary|United Kingdom 1
Bulgaria|Israel 1
Bulgaria|Macedonia, The Former Yugoslav Republic of|Poland|Russian Federation 1
Côte D’Ivoire 1
Chile|Argentina|Bulgaria|Colombia|Czechia|Poland|Romania|Russian Federation|Ukraine|United Kingdom 1
China|Hong Kong|Malaysia|Thailand 1
Colombia|Czechia|Japan|Poland|Romania|Chile|Argentina|Brazil|Bulgaria|Russian Federation|Spain|Sweden|Ukraine|United Kingdom 1
Croatia|North Macedonia|Ukraine 1
Denmark 1
Denmark|Germany|Netherlands 1
Finland|Georgia|Italy|Romania|Serbia|Spain|Sweden|Turkey|Ukraine 1
France|Germany|Israel 1
France|Germany|Italy|Netherlands|Spain|Turkey|Ukraine 1
France|Hungary|Israel|Poland|Spain|Turkey|United Kingdom 1
France|South Africa|United Kingdom 1
Georgia|Moldova, Republic of|United Kingdom 1
Germany 1
Germany|Greece|Italy|Spain|Sweden|United Kingdom 1
Germany|Greece|Italy|Spain|United Kingdom 1
Germany|Israel|Italy|Spain|Switzerland 1
Germany|Japan|Spain 1
Germany|Latvia|Malaysia|Spain 1
India|Poland|Romania|Russian Federation|Ukraine|United Kingdom 1
India|United States|Australia|Austria|Belgium|Brazil|Canada|France|Germany|Hong Kong|Israel|Italy|Japan|New Zealand|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
Iran, Islamic Republic of 1
Iran, Islamic Republic of|Turkey 1
Italy 1
Japan 1
Japan|United States|Australia|Brazil|Canada|Croatia|Denmark|France|Germany|Greece|Hungary|Israel|Italy|Korea, Republic of|Lithuania|Malaysia|Netherlands|Norway|Portugal|Puerto Rico|Spain|Switzerland|Taiwan|Turkey|Ukraine|United Kingdom 1
Malaysia|United Kingdom 1
Moldova, Republic of|South Africa|Ukraine 1
Netherlands 1
Norway 1
Poland|Romania|Russian Federation 1
Poland|South Africa|United Kingdom 1
Poland|Ukraine 1
Poland|United States|Brazil|Chile|Croatia|South Africa|Switzerland 1
Portugal 1
Romania|United States|Argentina|Bulgaria 1
Russian Federation|Ukraine 1
South Africa 1
Spain|Sweden|United States|Austria|Canada|Croatia|Denmark|Greece|Israel|Italy|Japan|Malaysia|Ukraine|United Kingdom 1
Taiwan 1
United States|Algeria|Argentina|Australia|Austria|Bulgaria|Canada|France|Germany|Greece|Israel|Italy|Japan|Malaysia|Romania|Spain|Taiwan|Thailand 1
United States|Algeria|Argentina|Australia|Austria|Canada|France|Germany|Israel|Italy|Japan|Malaysia|Netherlands|Spain|Taiwan|Thailand|United Kingdom 1
United States|Algeria|Austria|Brazil|China|Denmark|Greece|Hong Kong|Hungary|Japan|Lithuania|Poland|Portugal|Puerto Rico|Russian Federation|Serbia|Spain|Turkey 1
United States|Argentina|Austria|Brazil|Chile|Egypt|India|Iran, Islamic Republic of|Italy|Mexico|Saudi Arabia|South Africa|Spain|Turkey 1
United States|Argentina|Austria|Colombia|Croatia|Jordan|Mexico|New Zealand|Oman|Peru|Poland|Romania|Turkey 1
United States|Argentina|Austria|Croatia|Denmark|Germany|Hong Kong|India|Indonesia|Israel|Italy|Norway|Pakistan|Poland|Serbia|South Africa|Spain|Sweden|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Argentina|Brazil|Bulgaria|France|Philippines|Poland|Romania|Russian Federation|South Africa|Spain|Turkey 1
United States|Argentina|Brazil|Canada|Croatia|France|Hungary|Israel|Italy|Japan|Malaysia|Poland|South Africa|Spain|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Argentina|Bulgaria|Canada|Denmark|Hungary|Ireland|Israel|Italy|Latvia|Lithuania|Mexico|Norway|Poland|Romania|Russian Federation|Spain 1
United States|Argentina|China|Colombia|Czech Republic|India|Indonesia|Japan|Mexico|Romania|Russian Federation|Serbia|Slovakia|South Africa|Taiwan|Thailand|Turkey|Ukraine 1
United States|Australia|Austria|Belgium|Brazil|Canada|France|Germany|Hong Kong|India|Ireland|Israel|Italy|Japan|Netherlands|New Zealand|Poland|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Austria|Bulgaria|Canada|Czechia|France|Germany|Israel|Italy|Japan|Malaysia|Philippines|South Africa|Spain 1
United States|Australia|Austria|Bulgaria|Czechia|Germany|Israel|Japan|Korea, Republic of|Lithuania|Malaysia|Netherlands|Poland|Romania|Spain|Sweden|Switzerland|Taiwan|Ukraine|United Kingdom 1
United States|Australia|Austria|Bulgaria|France|Germany|Hong Kong|Hungary|Israel|Italy|Malaysia|Norway|Poland|Romania|Singapore|Spain|Sweden|Switzerland|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Canada|Czech Republic|Germany|Hungary|Italy|Japan|Lebanon|Malaysia|Netherlands|Philippines|Poland|Romania|Russian Federation|South Africa|Spain|Ukraine|United Kingdom 1
United States|Australia|Austria|Canada|Czechia|France|Georgia|Germany|Hungary|Ireland|Italy|Japan|Lebanon|Malaysia|Netherlands|Philippines|Poland|Portugal|Romania|South Africa|Spain|Switzerland|Thailand|Ukraine|United Kingdom 1
United States|Australia|Austria|Croatia|France|Germany|Israel|Malaysia|Netherlands|Poland|Spain|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|France|Georgia|Germany|Italy|Lebanon|Malaysia|Netherlands|Philippines|Poland|Portugal|Romania|Spain|Switzerland|Thailand|Turkey|Ukraine 1
United States|Australia|Austria|Hungary|New Zealand|Poland|Romania|Sweden 1
United States|Australia|Belgium|Brazil|Canada|China|France|Germany|Hong Kong|India|Ireland|Italy|Japan|Netherlands|Poland|South Africa|Sweden|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|China|France|Germany|Hong Kong|India|Italy|Japan|Poland|Russian Federation|South Africa|Sweden|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|France|Germany|Greece|Israel|Italy|Japan|Korea, Republic of|Saudi Arabia|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
United States|Australia|Belgium|Brazil|France|Germany|Israel|Italy|Korea, Republic of|South Africa|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Denmark|France|Germany|Ireland|Italy|Netherlands|New Zealand|Poland|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Belgium|Japan|Poland|Spain 1
United States|Australia|Brazil|Bulgaria|Chile|China|Colombia|Denmark|France|Germany|Hungary|India|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|New Zealand|Poland|Romania|Russian Federation|Singapore|South Africa|Sweden|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Brazil|Bulgaria|Croatia|Denmark|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Malaysia|Netherlands|Norway|Puerto Rico|Russian Federation|Spain|Sweden|Switzerland|Taiwan|Turkey|United Kingdom 1
United States|Australia|Brazil|Bulgaria|Croatia|Denmark|France|Germany|Hungary|Israel|Italy|Japan|Malaysia|Netherlands|Norway|Spain|Sweden|Switzerland|Taiwan|Turkey|United Kingdom 1
United States|Australia|Brazil|Canada|France|Germany|Ireland|Italy|Netherlands|New Zealand|Poland|Spain|Sweden|United Kingdom 1
United States|Australia|Canada 1
United States|Australia|Canada|China|Denmark|France|Germany|Ireland|Israel|Italy|Japan|Korea, Republic of|Malaysia|South Africa|Spain|Turkey|Ukraine|United Kingdom 1
United States|Australia|Canada|China|France|Germany|India|Italy|Japan|Korea, Republic of|Malaysia|South Africa|Spain|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Canada|Greece|Japan|Saudi Arabia|Sweden|Taiwan|Turkey|United Kingdom 1
United States|Australia|China|Denmark|France|Germany|Hungary|India|Israel|Italy|Japan|Korea, Republic of|Malaysia|South Africa|Spain|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Costa Rica|France|Germany|Ireland|Italy|Japan|Korea, Republic of|Poland|South Africa|Spain|Taiwan|United Kingdom 1
United States|Australia|Costa Rica|France|Germany|Italy|Japan|Korea, Republic of|New Zealand|Poland|South Africa|Spain|Taiwan|United Kingdom 1
United States|Australia|Denmark|Germany|Hungary|India|Ireland|Israel|Italy|Japan|Korea, Republic of|Malaysia|South Africa|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Hong Kong|Ireland|Netherlands|Poland|South Africa|United Kingdom 1
United States|Australia|Ireland|Netherlands|South Africa|United Kingdom 1
United States|Australia|New Zealand 1
United States|Austria|Belgium|Bulgaria|Canada|Denmark|Finland|France|Germany|Hong Kong|Hungary|Italy|Korea, Republic of|Malaysia|Netherlands|Norway|Singapore|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Austria|Belgium|Canada|Colombia|Denmark|France|Germany|Israel|Italy|Japan|Korea, Republic of|Netherlands|Norway|Poland|Romania|Singapore|Taiwan|Turkey|United Kingdom 1
United States|Austria|Belgium|Canada|France|Germany|Italy|Sweden|United Kingdom 1
United States|Austria|Belgium|France|Hungary|Italy|Netherlands|Norway|Poland|Portugal|Romania|Russian Federation|Spain|Sweden 1
United States|Austria|Brazil|Croatia|Greece|Hungary|Italy|Japan|Malaysia|Poland|Puerto Rico|Romania|Russian Federation|Serbia|South Africa|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Austria|Bulgaria|France|Germany|Israel|Italy|Japan|Russian Federation|Spain 1
United States|Austria|Bulgaria|Germany|Serbia|Spain|Taiwan 1
United States|Austria|Canada|France|Germany|Italy|Puerto Rico|Spain|Sweden|United Kingdom 1
United States|Austria|France|Germany|Greece|Italy|Japan|Macedonia, The Former Yugoslav Republic of|Malaysia|Netherlands|Romania|Russian Federation|South Africa|Spain|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Austria|France|Germany|Greece|Italy|Japan|Macedonia, The Former Yugoslav Republic of|Malaysia|Netherlands|Romania|South Africa|Spain|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Austria|France|Germany|Japan|Serbia 1
United States|Austria|France|Hungary|Spain 1
United States|Belarus|Bulgaria|Georgia|Israel|Poland|Romania|Russian Federation|Ukraine|United Kingdom 1
United States|Belarus|Canada|France|Georgia|Germany|India|Italy|Moldova, Republic of|Morocco|Poland|Portugal|Russian Federation|Slovenia|Spain|Ukraine|United Kingdom 1
United States|Belgium|Bulgaria|Canada|France|Germany|Italy|Japan|Spain|United Kingdom 1
United States|Belgium|Canada|France|Germany|Italy|Netherlands|Poland|South Africa|Spain|United Kingdom 1
United States|Belgium|Canada|Germany|Ireland|Italy|Slovenia|Sweden|United Kingdom 1
United States|Belgium|Denmark|Germany|Ireland|Italy|Netherlands|Sweden|United Kingdom 1
United States|Belgium|Hungary|Italy|New Zealand|South Africa|Turkey|United Kingdom 1
United States|Brazil|Bulgaria|Croatia|Japan|New Zealand|Poland|Romania|Russian Federation|Ukraine 1
United States|Brazil|Canada|Croatia|France|Germany|Italy|Japan|Malaysia|Taiwan|United Kingdom 1
United States|Brazil|Canada|France|Greece|Israel|Italy|Japan|Lithuania|Malaysia|Portugal|Puerto Rico|Switzerland|Turkey|Ukraine|United Kingdom 1
United States|Brazil|Croatia|Denmark|Former Serbia and Montenegro|Germany|Hungary|Israel|Italy|Japan|Malaysia|Russian Federation|Serbia|Spain|Switzerland|Taiwan|Turkey|United Kingdom 1
United States|Brazil|Croatia|Germany|Israel|Italy|Japan|Latvia|Lithuania|Macedonia, The Former Yugoslav Republic of|Malaysia|Poland|Puerto Rico|Russian Federation|Serbia|Spain|Switzerland|Taiwan|Turkey|United Kingdom 1
United States|Brazil|Former Serbia and Montenegro|France|Japan|Malaysia|Serbia|South Africa|Sweden|Turkey|United Kingdom 1
United States|Brazil|Italy|Japan|Lithuania|Macedonia, The Former Yugoslav Republic of|Malaysia|Poland|Puerto Rico|Russian Federation|Serbia|Taiwan|Turkey 1
United States|Bulgaria 1
United States|Bulgaria|France|Germany|Netherlands|Spain|United Kingdom 1
United States|Bulgaria|Germany 1
United States|Bulgaria|Hong Kong|India|Japan|Korea, Republic of|Russian Federation|Spain|Taiwan|Turkey 1
United States|Bulgaria|Hong Kong|Korea, Republic of|Malaysia|Netherlands|Spain|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Bulgaria|Lithuania|Netherlands|Russian Federation|Spain|Switzerland|Ukraine|United Kingdom 1
United States|Canada 1
United States|Canada|Croatia|Finland|France|Japan|Netherlands|North Macedonia|Slovenia 1
United States|Canada|Croatia|Hungary|Italy|Romania|Russian Federation|Serbia|Spain 1
United States|Canada|France|Georgia|India|Moldova, Republic of|Poland|Ukraine|United Kingdom 1
United States|Canada|France|Germany|Hungary|Italy|Japan|Macedonia, The Former Yugoslav Republic of|Malaysia|Netherlands|Russian Federation|South Africa|Thailand|Turkey|United Kingdom 1
United States|Canada|India|Italy|Russian Federation|Spain 1
United States|Canada|India|United Kingdom 1
United States|Canada|Italy|Spain 1
United States|Canada|Puerto Rico 1
United States|Chile|Croatia|Poland|South Africa|Switzerland 1
United States|Costa Rica|France|Germany|Italy|Japan|South Africa|Spain|Turkey|United Kingdom 1
United States|Denmark|France|Germany|Japan|Spain|Sweden|United Kingdom 1
United States|Denmark|France|Germany|Netherlands|Spain 1
United States|Denmark|France|United Kingdom 1
United States|France|Germany|Italy|Japan|Spain|Sweden|Thailand|Turkey|Ukraine|United Kingdom 1
United States|France|India|Israel|Italy|Poland|United Kingdom 1
United States|France|Israel|South Africa|United Kingdom 1
United States|France|Italy|Spain|United Kingdom 1
United States|Germany|Italy|Japan|Switzerland|Turkey|United Kingdom 1
United States|Germany|Italy|Poland|Spain|Switzerland 1
United States|Germany|Switzerland 1
United States|Greece|Japan|Malaysia|Romania|Serbia|Thailand 1
United States|Hong Kong|Israel 1
United States|Italy|United Kingdom 1
United States|Japan 1
United States|Japan|Poland|Romania|Russian Federation|Serbia|Spain|Taiwan|Ukraine 1
United States|Mexico|Russian Federation|South Africa|Spain|Ukraine 1
United States|Netherlands 1

Sites per Study

Site_count Study_Count
1 86
2 10
3 15
4 10
5 11
6 6
7 13
8 13
9 4
10 7
11 12
12 4
13 2
14 6
15 9
16 5
17 9
18 3
19 3
20 4
21 1
22 2
23 3
24 2
25 3
27 1
28 3
29 1
30 2
31 1
32 1
34 2
35 1
36 1
37 6
38 2
39 4
41 2
42 2
43 2
44 1
45 1
47 1
48 2
49 2
51 2
56 1
57 1
58 1
59 1
61 3
63 1
64 4
65 1
66 1
69 1
70 2
71 1
72 2
73 1
78 1
83 1
89 1
90 1
93 1

Phase

Phase Study_Count
Phase 3 107
Phase 1 59
Phase 4 45
N/A 42
Phase 2 25
Phase 1/Phase 2 15
Phase 2/Phase 3 15
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 139
2 88
3 30
4 12
5 5
6 4
9 1
10 1
NA 29

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 3 3.00000 2.00000 10.00000 3.00 4.00000 3.00000 1.0
1st Qu. 3 18.00000 13.50000 15.50000 13.00 23.00000 36.00000 20.0
Median 3 24.00000 18.00000 27.00000 22.00 50.00000 68.00000 32.0
Mean 3 62.87805 21.05085 24.33333 25.12 63.92308 81.82796 60.4
3rd Qu. 3 60.00000 27.00000 30.00000 26.00 77.00000 109.00000 60.0
Max. 3 600.00000 52.00000 52.00000 82.00 175.00000 250.00000 400.0

Trial Group Type

group_type Group_Count
Experimental 426
Active Comparator 49
NA 29
Other 27
Placebo Comparator 10
No Intervention 9

Intervention Model

intervention_model Study_Count
Single Group Assignment 156
Parallel Assignment 72
Crossover Assignment 46
NA 18
Sequential Assignment 15
Factorial Assignment 2

Primary Purpose

primary_purpose Study_Count
Treatment 235
Prevention 24
Other 16
Basic Science 11
NA 9
Diagnostic 7
Supportive Care 4
Screening 2
Health Services Research 1

Observational Studies

Studies by Country

Country Study_Count
United States 28
NA 15
France 11
Japan 6
Sweden 6
Canada 5
Korea, Republic of 5
Italy 4
China 3
Germany 3
Spain 3
United Kingdom 3
Austria|Germany 2
Brazil|Canada 2
Algeria|Austria|Belgium|Czech Republic|France|Germany|Italy|Netherlands|Poland|Portugal|Saudi Arabia|South Africa|Sweden|Turkey|United Kingdom|Venezuela 1
Algeria|Morocco|Oman|Saudi Arabia|United Arab Emirates 1
Argentina|Austria|Belgium|France|Germany|Hungary|Iran, Islamic Republic of|Ireland|Italy|Poland|Portugal|Slovakia|Sweden|United Kingdom 1
Australia|Austria|Belgium|Brazil|Canada|Colombia|Czechia|Denmark|France|Greece|Hungary|Italy|Norway|Poland|Portugal|Russian Federation|Slovenia|Spain|Sweden|Switzerland|United Kingdom 1
Australia|Austria|Belgium|Canada|Finland|Germany|Italy|Netherlands|Spain|United Kingdom 1
Austria 1
Austria|Belgium|Denmark|France|Greece|Italy|Netherlands|Spain|Sweden|Switzerland 1
Austria|Belgium|Finland|France|Italy|Norway|Spain|Sweden|United Kingdom 1
Austria|Belgium|France|Germany|Italy|Netherlands|Portugal|Spain|Sweden|United Kingdom 1
Austria|Belgium|France|Germany|Italy|Spain|Switzerland 1
Austria|Canada|Germany|Norway|Portugal 1
Austria|Germany|Greece|Italy|Netherlands|Slovenia|Spain 1
Austria|Germany|Italy|Netherlands 1
Bahrain|Bosnia and Herzegovina|Croatia|Germany|Israel|Kazakhstan|Kuwait|Libyan Arab Jamahiriya|Morocco|Oman|Qatar|Romania|Russian Federation|Saudi Arabia|Slovenia|Tunisia|United Arab Emirates 1
Belgium 1
Belgium|Bulgaria|Croatia|Czechia|Estonia|Finland|Germany|Greece|Hungary|Italy|Kuwait|Luxembourg|Netherlands|Oman|Portugal|Qatar|Saudi Arabia|Slovenia|Spain|Sweden|Switzerland|United Arab Emirates|United Kingdom 1
Belgium|France|Germany|Italy|Spain|Sweden|United Kingdom 1
Brazil 1
Canada|Spain|United Kingdom 1
Denmark|Finland|Sweden 1
Denmark|Japan 1
Ecuador 1
France|Germany|Hungary|United Kingdom 1
France|Germany|Ireland|Italy|Kuwait|Norway|Saudi Arabia|Switzerland|United Arab Emirates 1
France|Italy 1
Greece 1
Greece|Ireland|Italy|Norway|Saudi Arabia|Sweden|United Arab Emirates|United Kingdom 1
India|Morocco|Oman|South Africa 1
Mexico 1
Mexico|Venezuela 1
Norway 1
Portugal 1
Taiwan 1
Turkey 1
United States|Algeria|Australia|Austria|Bulgaria|Canada|Croatia|Finland|France|Germany|Greece|India|Israel|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Netherlands|Norway|Poland|Portugal|Russian Federation|Serbia|Slovakia|South Africa|Spain|Sweden|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Belarus|Czechia|Ecuador|France|Guatemala|Italy|Lithuania|Norway|Portugal|Slovakia|United Kingdom 1
United States|Argentina|Canada|Croatia|Czech Republic|France|Germany|Ireland|Italy|Slovakia|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Canada|Thailand 1
United States|Australia|China|Costa Rica|Germany|Italy|Japan|Korea, Republic of|Poland|South Africa|Spain|Taiwan 1
United States|Australia|Germany|Israel|Italy|Japan|Netherlands|Sweden|Taiwan 1
United States|Austria|Belgium|Brazil|Canada|China|Colombia|Denmark|France|Germany|Greece|Italy|Japan|Kuwait|Luxembourg|Mexico|Netherlands|Norway|Portugal|Saudi Arabia|Slovenia|Spain|Sweden|Switzerland|Taiwan|United Arab Emirates 1
United States|Austria|Belgium|Canada|France|Germany|Italy|Spain|United Kingdom 1
United States|Austria|Czechia|France|Germany|Greece|Hungary|Italy|Netherlands|Poland|Slovakia|Slovenia|Spain|Sweden|Switzerland 1
United States|Austria|France|Germany|Italy|Spain 1
United States|Austria|Italy|Netherlands|Sweden 1
United States|Azerbaijan|Belarus|Belgium|Canada|Estonia|France|Germany|Italy|Lithuania|Russian Federation|Spain|Turkey|United Kingdom 1
United States|Belgium|Canada|Colombia|France|Germany|Greece|Italy|Luxembourg|Netherlands|Slovenia|Spain|Taiwan 1
United States|Brazil|Canada|France|Germany|Greece|Italy|Sweden 1
United States|Canada 1
United States|Canada|Germany|United Kingdom 1
United States|Canada|Israel|Singapore|United Kingdom 1
United States|Germany 1
United States|Japan|Spain|United Kingdom 1
United States|Puerto Rico 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 66
2 9
3 2
4 7
5 6
6 2
7 7
9 1
10 3
11 2
12 2
13 1
14 3
16 3
17 6
18 1
19 2
21 1
22 3
23 1
24 1
25 2
26 1
27 3
31 1
32 1
34 1
35 1
36 1
37 1
38 1
39 1
41 1
48 1
52 2
91 1
93 1
95 1
136 1

Enrollment Metrics

Measure Observational
Min 4.0000
1st Qu 42.0000
Median 81.5000
Mean 243.7466
3rd Qu 200.0000
Max 3520.0000

Observation Model

observational_model Study_Count
Cohort 101
Case-Only 18
NA 17
Other 7
Ecologic or Community 3
Family-Based 2
Case-Control 1
Defined Population 1
Natural History 1

Time Perspective

time_perspective Study_Count
Prospective 90
Retrospective 21
Cross-Sectional 16
Other 11
NA 11
Cross-Sectional, Retrospective 1
Longitudinal, Prospective 1

Registries

Studies by Country

Country Study_Count
United States 3
Spain 2
Canada 1
Germany 1
NA 1
Sweden 1
Switzerland 1
Turkey 1

Sites per Study

Site_count Study_Count
1 7
2 2
20 1
38 1

Enrollment Metrics

Measure Registries
Min 17.0000
1st Qu 35.0000
Median 100.0000
Mean 209.9091
3rd Qu 290.0000
Max 900.0000

Registry Model

observational_model Study_Count
Cohort 7
Case-Control 2
Ecologic or Community 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 8
Cross-Sectional 2
Other 1

Follow-up

target_duration Study_Count
1 Day 2
2 Years 2
5 Years 2
1 Month 1
10 Years 1
4 Years 1
5 Months 1
7 Days 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03364998 BAY94-9027 PK Study Comparing to Another Long Acting Product https://ClinicalTrials.gov/show/NCT03364998 Completed Bayer 2018-01-25
NCT03095287 Alphanate in Immune Tolerance Induction Therapy https://ClinicalTrials.gov/show/NCT03095287 Recruiting Grifols Therapeutics LLC 2021-10-31
NCT03995784 Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B https://ClinicalTrials.gov/show/NCT03995784 Completed Catalyst Biosciences 2020-02-28
NCT03588299 Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a “Shuttle”. https://ClinicalTrials.gov/show/NCT03588299 Recruiting Bayer 2022-05-31
NCT03407651 Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B https://ClinicalTrials.gov/show/NCT03407651 Completed Catalyst Biosciences 2019-03-15
NCT03380780 A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers https://ClinicalTrials.gov/show/NCT03380780 Completed Hoffmann-La Roche 2018-09-18
NCT03379974 Exercise Versus DDAVP in Patients With Mild Hemophilia A https://ClinicalTrials.gov/show/NCT03379974 Completed Nationwide Children’s Hospital 2019-08-30
NCT03376516 Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A https://ClinicalTrials.gov/show/NCT03376516 Completed Octapharma 2018-11-03
NCT03370913 Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients https://ClinicalTrials.gov/show/NCT03370913 Active, not recruiting BioMarin Pharmaceutical 2022-12-31
NCT03370172 Safety and Dose Escalation Study of an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia A Participants https://ClinicalTrials.gov/show/NCT03370172 Active, not recruiting Shire 2021-09-30
NCT03369444 A Factor IX Gene Therapy Study (FIX-GT) https://ClinicalTrials.gov/show/NCT03369444 Recruiting University College, London 2021-01-01
NCT03485170 PET Imaging of Hemophilic Arthropathy https://ClinicalTrials.gov/show/NCT03485170 Completed Tri-Service General Hospital 2018-12-31
NCT03363321 PF-06741086 Long-term Treatment in Severe Hemophilia https://ClinicalTrials.gov/show/NCT03363321 Recruiting Pfizer 2020-08-11
NCT03307980 Long-term Safety and Efficacy Study of SPK-9001 in Individuals With Hemophilia B https://ClinicalTrials.gov/show/NCT03307980 Recruiting Pfizer 2026-10-06
NCT03272568 Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers https://ClinicalTrials.gov/show/NCT03272568 Completed Emory University 2019-12-31
NCT03205163 A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A) https://ClinicalTrials.gov/show/NCT03205163 Completed Bioverativ Therapeutics Inc. 2018-11-12
NCT03196297 A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors https://ClinicalTrials.gov/show/NCT03196297 Completed Novo Nordisk A/S 2018-06-22
NCT03196284 A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors https://ClinicalTrials.gov/show/NCT03196284 Completed Novo Nordisk A/S 2018-09-19
NCT03191799 A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors https://ClinicalTrials.gov/show/NCT03191799 Active, not recruiting Hoffmann-La Roche 2020-09-04
NCT03186677 Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients https://ClinicalTrials.gov/show/NCT03186677 Completed ISU Abxis Co., Ltd. 2018-10-10
NCT03103542 Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies https://ClinicalTrials.gov/show/NCT03103542 Active, not recruiting Swedish Orphan Biovitrum 2019-09-04
NCT03075670 A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B https://ClinicalTrials.gov/show/NCT03075670 Completed Novo Nordisk A/S 2017-12-08
NCT03054662 Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast. https://ClinicalTrials.gov/show/NCT03054662 Completed Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2018-12-31
NCT03020160 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A https://ClinicalTrials.gov/show/NCT03020160 Active, not recruiting Hoffmann-La Roche 2017-12-15
NCT03003533 A Gene Transfer Study for Hemophilia A https://ClinicalTrials.gov/show/NCT03003533 Recruiting Spark Therapeutics 2020-05-31
NCT03001830 Gene Therapy for Haemophilia A. https://ClinicalTrials.gov/show/NCT03001830 Recruiting University College, London 2020-12-31
NCT02994407 Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A https://ClinicalTrials.gov/show/NCT02994407 Completed Novo Nordisk A/S 2018-10-15
NCT02974855 PF-06741086 Multiple Dose Study in Severe Hemophilia https://ClinicalTrials.gov/show/NCT02974855 Completed Pfizer 2018-12-03
NCT02954575 Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT02954575 Completed Octapharma 2018-03-29
NCT02941354 Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A https://ClinicalTrials.gov/show/NCT02941354 Completed Novo Nordisk A/S 2017-06-20
NCT02938585 Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A https://ClinicalTrials.gov/show/NCT02938585 Completed Novo Nordisk A/S 2018-03-16
NCT02920398 A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A https://ClinicalTrials.gov/show/NCT02920398 Completed Novo Nordisk A/S 2017-04-07
NCT02919800 A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male https://ClinicalTrials.gov/show/NCT02919800 Completed OPKO Health, Inc. 2018-02-21
NCT02870452 Effectiveness of Psychological Interventions in Haemophilia https://ClinicalTrials.gov/show/NCT02870452 Completed University of Minho 2018-12-31
NCT02851082 Could Physical Activity Help to Counteract the Blood Haemophilia Disturbance? A Pilot Study. https://ClinicalTrials.gov/show/NCT02851082 Completed University Hospital, Toulouse 2017-01-31
NCT02847637 A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors https://ClinicalTrials.gov/show/NCT02847637 Active, not recruiting Hoffmann-La Roche 2017-09-15
NCT02825667 Effectiveness of the Myofascial Therapy in the Hemophilic Arthropathy of Ankle https://ClinicalTrials.gov/show/NCT02825667 Completed Real Fundación Victoria Eugenia 2017-09-08
NCT02803502 Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ? https://ClinicalTrials.gov/show/NCT02803502 Recruiting Brugmann University Hospital 2020-07-31
NCT02795767 A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors https://ClinicalTrials.gov/show/NCT02795767 Active, not recruiting Hoffmann-La Roche 2018-04-30
NCT02781766 TGA (Thrombin Generation Assay) and Prophylaxis in Haemophilia https://ClinicalTrials.gov/show/NCT02781766 Recruiting Hospices Civils de Lyon 2019-09-08
NCT02781233 A Progressive Resistance Training Program in Patients With Haemophilia https://ClinicalTrials.gov/show/NCT02781233 Completed University of Valencia 2018-06-25
NCT02764489 FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR) https://ClinicalTrials.gov/show/NCT02764489 Recruiting Shire 2021-03-30
NCT02727647 Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients https://ClinicalTrials.gov/show/NCT02727647 Completed Chulalongkorn University 2016-03-31
NCT02716194 BAX 826 Dose-Escalation Safety Study https://ClinicalTrials.gov/show/NCT02716194 Completed Shire 2017-01-17
NCT02697370 Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A https://ClinicalTrials.gov/show/NCT02697370 Completed Hampshire Hospitals NHS Foundation Trust 2015-05-31
NCT02695160 Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B https://ClinicalTrials.gov/show/NCT02695160 Active, not recruiting Sangamo Therapeutics 2021-01-31
NCT02622321 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors https://ClinicalTrials.gov/show/NCT02622321 Active, not recruiting Hoffmann-La Roche 2016-10-25
NCT02615691 Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Recombinant FVIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years of Age With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT02615691 Active, not recruiting Shire 2023-06-29
NCT02601170 Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy https://ClinicalTrials.gov/show/NCT02601170 Completed Tri-Service General Hospital 2015-04-30
NCT02585960 BAX 855 PK-guided Dosing https://ClinicalTrials.gov/show/NCT02585960 Completed Shire 2018-08-05
NCT02582060 Individualizing Hemophilia Prophylaxis Using Thromboelastography https://ClinicalTrials.gov/show/NCT02582060 Completed Children’s Hospital Los Angeles 2017-12-31
NCT03093480 A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study) https://ClinicalTrials.gov/show/NCT03093480 Active, not recruiting Sanofi 2021-02-15
NCT02576795 Gene Therapy Study in Severe Haemophilia A Patients https://ClinicalTrials.gov/show/NCT02576795 Active, not recruiting BioMarin Pharmaceutical 2022-02-28
NCT03061201 Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT03061201 Recruiting Pfizer 2024-07-23
NCT02571569 A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors https://ClinicalTrials.gov/show/NCT02571569 Completed Bayer 2018-07-09
NCT02554773 An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B https://ClinicalTrials.gov/show/NCT02554773 Active, not recruiting Sanofi 2023-02-28
NCT03392974 Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg https://ClinicalTrials.gov/show/NCT03392974 Active, not recruiting BioMarin Pharmaceutical 2022-12-01
NCT02548143 LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures https://ClinicalTrials.gov/show/NCT02548143 Completed LFB USA, Inc. 2017-08-06
NCT02541942 Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adeptâ„¢2 Trial https://ClinicalTrials.gov/show/NCT02541942 Completed Novo Nordisk A/S 2016-04-15
NCT02528968 National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A https://ClinicalTrials.gov/show/NCT02528968 Completed Hampshire Hospitals NHS Foundation Trust 2017-11-30
NCT02506023 Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers https://ClinicalTrials.gov/show/NCT02506023 Completed Emory University 2018-06-15
NCT02502149 Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale https://ClinicalTrials.gov/show/NCT02502149 Completed Bioverativ Therapeutics Inc. 2017-04-30
NCT02492984 PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A https://ClinicalTrials.gov/show/NCT02492984 Completed Pfizer 2016-07-31
NCT02490787 Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects https://ClinicalTrials.gov/show/NCT02490787 Completed Novo Nordisk A/S 2016-10-14
NCT02484092 A Gene Therapy Study for Hemophilia B https://ClinicalTrials.gov/show/NCT02484092 Completed Pfizer 2019-04-08
NCT02483208 Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate https://ClinicalTrials.gov/show/NCT02483208 Completed Bayer 2015-07-31
NCT02461992 Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A https://ClinicalTrials.gov/show/NCT02461992 Completed Pfizer 2015-08-31
NCT02418793 A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B https://ClinicalTrials.gov/show/NCT02418793 Completed OPKO Health, Inc. 2018-09-30
NCT02396342 Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B https://ClinicalTrials.gov/show/NCT02396342 Active, not recruiting UniQure Biopharma B.V. 2021-05-31
NCT02362581 Comparison of Prophylaxis and On-demand Treatment in Children With Moderate to Severe Hemophilia A https://ClinicalTrials.gov/show/NCT02362581 Completed Chulalongkorn University 2014-01-31
NCT02336178 Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China https://ClinicalTrials.gov/show/NCT02336178 Completed Pfizer 2016-07-31
NCT02306694 Prospective Biomarkers of Bone Metabolism in Hemophilia A https://ClinicalTrials.gov/show/NCT02306694 Completed Oregon Health and Science University 2018-04-16
NCT02284789 Colorado Adult Joint Assessment Scale (CAJAS) Validation https://ClinicalTrials.gov/show/NCT02284789 Completed Bayer 2015-10-31
NCT02263469 A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years https://ClinicalTrials.gov/show/NCT02263469 Completed Bio Products Laboratory 2006-07-31
NCT02263456 A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B https://ClinicalTrials.gov/show/NCT02263456 Completed Bio Products Laboratory 2001-09-30
NCT02250573 An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery https://ClinicalTrials.gov/show/NCT02250573 Completed Bio Products Laboratory 2006-04-30
NCT02250560 A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery. https://ClinicalTrials.gov/show/NCT02250560 Completed Bio Products Laboratory 2003-11-30
NCT02250482 An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery. https://ClinicalTrials.gov/show/NCT02250482 Completed Bio Products Laboratory 2003-08-31
NCT02246894 A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A. https://ClinicalTrials.gov/show/NCT02246894 Completed Bio Products Laboratory 2005-01-31
NCT02246881 A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A. https://ClinicalTrials.gov/show/NCT02246881 Completed Bio Products Laboratory 2004-01-31
NCT02246868 An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients. https://ClinicalTrials.gov/show/NCT02246868 Completed Bio Products Laboratory 2004-08-31
NCT02234323 An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT02234323 Completed Bioverativ Therapeutics Inc. 2019-09-23
NCT02234310 Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B https://ClinicalTrials.gov/show/NCT02234310 Completed Bioverativ Therapeutics Inc. 2019-08-20
NCT02231944 An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients https://ClinicalTrials.gov/show/NCT02231944 Completed Bio Products Laboratory 2003-10-31
NCT02213250 An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B https://ClinicalTrials.gov/show/NCT02213250 Completed Pfizer 2015-04-30
NCT02210091 BAX 855 Pediatric Study https://ClinicalTrials.gov/show/NCT02210091 Completed Shire 2015-10-23
NCT02198040 Physiotherapy in the Haemophilic Arthropathy of the Elbow. https://ClinicalTrials.gov/show/NCT02198040 Completed Universidad Católica San Antonio de Murcia 2012-10-31
NCT02198014 Manual Therapy in Haemophilic Arthropathy of the Knee https://ClinicalTrials.gov/show/NCT02198014 Completed Universidad Católica San Antonio de Murcia 2012-10-31
NCT02141074 Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B https://ClinicalTrials.gov/show/NCT02141074 Recruiting Novo Nordisk A/S 2022-10-30
NCT02093897 Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT02093897 Completed CSL Behring 2015-08-31
NCT02083965 Pharmacokinetics of rFVIIIFc at Two Vial Strengths https://ClinicalTrials.gov/show/NCT02083965 Completed Bioverativ Therapeutics Inc. 2014-10-31
NCT03384277 Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab https://ClinicalTrials.gov/show/NCT03384277 Recruiting Institute of Hematology & Blood Diseases Hospital 2021-10-30
NCT01311648 BAY81-8973 Pediatric Safety and Efficacy Trial https://ClinicalTrials.gov/show/NCT01311648 Active, not recruiting Bayer 2019-09-09
NCT01288391 Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients https://ClinicalTrials.gov/show/NCT01288391 Completed Novo Nordisk A/S 2011-07-31
NCT01286779 BAX 326 (rFIX) Continuation Study https://ClinicalTrials.gov/show/NCT01286779 Completed Shire 2017-06-29
NCT01272206 Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects https://ClinicalTrials.gov/show/NCT01272206 Completed Novo Nordisk A/S 2011-03-31
NCT02035605 A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients https://ClinicalTrials.gov/show/NCT02035605 Completed Alnylam Pharmaceuticals 2017-07-20
NCT02020369 Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors https://ClinicalTrials.gov/show/NCT02020369 Completed rEVO Biologics 2015-07-31
NCT04158648 A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors https://ClinicalTrials.gov/show/NCT04158648 Recruiting Hoffmann-La Roche 2022-07-19
NCT03315455 Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants https://ClinicalTrials.gov/show/NCT03315455 Active, not recruiting Hoffmann-La Roche 2021-03-09
NCT01992549 Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII https://ClinicalTrials.gov/show/NCT01992549 Completed Octapharma 2018-12-27
NCT01949792 A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors https://ClinicalTrials.gov/show/NCT01949792 Completed Novo Nordisk A/S 2013-11-30
NCT01945593 BAX 855 Continuation https://ClinicalTrials.gov/show/NCT01945593 Completed Shire 2018-03-02
NCT01921855 Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors https://ClinicalTrials.gov/show/NCT01921855 Completed Bayer 2009-12-31
NCT01913405 Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures https://ClinicalTrials.gov/show/NCT01913405 Completed Shire 2016-09-23
NCT01863758 Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A https://ClinicalTrials.gov/show/NCT01863758 Completed Octapharma 2015-01-31
NCT01810666 Prophylaxis Versus on Demand Treatment for Children With Hemophilia A https://ClinicalTrials.gov/show/NCT01810666 Completed Bayer 2014-01-31
NCT01800435 A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor https://ClinicalTrials.gov/show/NCT01800435 Completed Oslo University Hospital 2012-10-31
NCT01775618 Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A https://ClinicalTrials.gov/show/NCT01775618 Completed Bayer 2015-03-19
NCT01757405 Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen https://ClinicalTrials.gov/show/NCT01757405 Completed Shire 2014-11-11
NCT01748201 Viscosupplementation in Patients With Hemophilic Arthropathy https://ClinicalTrials.gov/show/NCT01748201 Completed University of Sao Paulo General Hospital 2013-03-31
NCT01736475 Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study) https://ClinicalTrials.gov/show/NCT01736475 Completed Shire 2014-07-17
NCT01731600 A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A https://ClinicalTrials.gov/show/NCT01731600 Completed Novo Nordisk A/S 2014-09-15
NCT01712438 Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients https://ClinicalTrials.gov/show/NCT01712438 Completed Octapharma 2018-12-14
NCT01708564 A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B https://ClinicalTrials.gov/show/NCT01708564 Completed rEVO Biologics 2013-06-30
NCT01704521 Viral Kinetics in HCV Clearance in Subjects With Hemophilia https://ClinicalTrials.gov/show/NCT01704521 Completed University of Cincinnati 2014-10-31
NCT01692925 Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A https://ClinicalTrials.gov/show/NCT01692925 Completed Novo Nordisk A/S 2013-03-31
NCT01687608 Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B https://ClinicalTrials.gov/show/NCT01687608 Active, not recruiting Shire 2030-10-28
NCT01662531 A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B https://ClinicalTrials.gov/show/NCT01662531 Completed CSL Behring 2014-10-31
NCT01653639 Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222 https://ClinicalTrials.gov/show/NCT01653639 Completed Bayer 2012-12-31
NCT01625390 A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150 https://ClinicalTrials.gov/show/NCT01625390 Completed Bayer 2014-03-31
NCT01599819 BAX 855 Dose-Escalation Safety Study https://ClinicalTrials.gov/show/NCT01599819 Completed Shire 2012-08-31
NCT01580293 A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A https://ClinicalTrials.gov/show/NCT01580293 Completed Bayer 2014-06-13
NCT01579903 Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC) https://ClinicalTrials.gov/show/NCT01579903 Completed Pfizer 2013-01-31
NCT01568580 Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A https://ClinicalTrials.gov/show/NCT01568580 Completed Green Cross Corporation 2006-09-30
NCT01563471 Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers https://ClinicalTrials.gov/show/NCT01563471 Completed Novo Nordisk A/S 2002-07-31
NCT01562587 Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State https://ClinicalTrials.gov/show/NCT01562587 Completed Novo Nordisk A/S 2003-05-31
NCT01561924 Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography https://ClinicalTrials.gov/show/NCT01561924 Completed Novo Nordisk A/S 2006-05-31
NCT01561417 Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects https://ClinicalTrials.gov/show/NCT01561417 Completed Novo Nordisk A/S 2006-09-30
NCT01561391 Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery https://ClinicalTrials.gov/show/NCT01561391 Completed Novo Nordisk A/S 2004-05-31
NCT01555749 Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects https://ClinicalTrials.gov/show/NCT01555749 Completed Novo Nordisk A/S 2012-05-08
NCT01507896 BAX 326 Surgery Study in Hemophilia B Patients https://ClinicalTrials.gov/show/NCT01507896 Completed Shire 2014-05-15
NCT01493778 Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A https://ClinicalTrials.gov/show/NCT01493778 Completed Novo Nordisk A/S 2017-08-16
NCT01489111 Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. https://ClinicalTrials.gov/show/NCT01489111 Completed Novo Nordisk A/S 2018-12-10
NCT01488994 BAX 326 Pediatric Study https://ClinicalTrials.gov/show/NCT01488994 Completed Shire 2013-05-14
NCT01486927 An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT01486927 Completed CSL Behring 2014-12-31
NCT01480180 Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A https://ClinicalTrials.gov/show/NCT01480180 Completed Novo Nordisk A/S 2018-12-10
NCT01477437 Internet-based Educational Program to Promote Self-Management for Teens With Hemophilia https://ClinicalTrials.gov/show/NCT01477437 Completed The Hospital for Sick Children 2013-03-31
NCT01467427 Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. https://ClinicalTrials.gov/show/NCT01467427 Active, not recruiting Novo Nordisk A/S 2014-03-30
NCT01458106 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A https://ClinicalTrials.gov/show/NCT01458106 Completed Bioverativ Therapeutics Inc. 2013-12-31
NCT01454739 Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A https://ClinicalTrials.gov/show/NCT01454739 Completed Bioverativ Therapeutics Inc. 2017-10-31
NCT01440946 Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B https://ClinicalTrials.gov/show/NCT01440946 Completed Bioverativ Therapeutics Inc. 2014-11-30
NCT01439971 Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia https://ClinicalTrials.gov/show/NCT01439971 Completed Catalyst Biosciences 2015-10-31
NCT01425723 Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B https://ClinicalTrials.gov/show/NCT01425723 Completed Bioverativ Therapeutics Inc. 2017-10-31
NCT01395810 Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 https://ClinicalTrials.gov/show/NCT01395810 Completed Novo Nordisk A/S 2014-03-30
NCT01392547 Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors https://ClinicalTrials.gov/show/NCT01392547 Completed Novo Nordisk A/S 2012-08-31
NCT01386528 Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B https://ClinicalTrials.gov/show/NCT01386528 Completed Novo Nordisk A/S 2013-12-01
NCT01365520 A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A https://ClinicalTrials.gov/show/NCT01365520 Completed Novo Nordisk A/S 2011-09-30
NCT01361126 A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B https://ClinicalTrials.gov/show/NCT01361126 Completed CSL Behring 2012-06-30
NCT01341912 Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs) https://ClinicalTrials.gov/show/NCT01341912 Completed Octapharma 2012-08-31
NCT01335061 Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B https://ClinicalTrials.gov/show/NCT01335061 Completed Pfizer 2014-04-30
NCT01333111 Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients https://ClinicalTrials.gov/show/NCT01333111 Completed Novo Nordisk A/S 2013-03-31
NCT04396639 Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients https://ClinicalTrials.gov/show/NCT04396639 Recruiting Pfizer 2021-04-05
NCT04394286 A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects https://ClinicalTrials.gov/show/NCT04394286 Recruiting Shire 2024-03-16
NCT04384341 Haemophilia and Bone Loss - PHILEOS Study https://ClinicalTrials.gov/show/NCT04384341 Recruiting Centre Hospitalier Universitaire de Saint Etienne 2022-04-30
NCT04309903 The Effects of Manual Therapy in Hemophilic Patients https://ClinicalTrials.gov/show/NCT04309903 Completed Necmettin Erbakan University 2019-04-15
NCT04308876 Effectiveness of Manual Therapy and Strengthening Exercises in Hemophilic Arthropathy of the Elbow Joint https://ClinicalTrials.gov/show/NCT04308876 Completed Necmettin Erbakan University 2019-03-10
NCT04303936 PHYSICAL ACTIVITY AND FVIII CLEARANCE: RELEVANCE FOR PERSONALIZED THERAPY IN SEVERE HAEMOPHILIA A (PHYSEMO) https://ClinicalTrials.gov/show/NCT04303936 Recruiting Catholic University of the Sacred Heart 2020-12-30
NCT04286412 Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophelia B https://ClinicalTrials.gov/show/NCT04286412 Recruiting Pfizer 2020-11-05
NCT04205188 The Effects of Therapeutic Exercises on Kinesiophobia in Haemophilic Patients. https://ClinicalTrials.gov/show/NCT04205188 Recruiting Cukurova University 2019-12-13
NCT04204408 A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People and Patients With Bleeding Disorder https://ClinicalTrials.gov/show/NCT04204408 Recruiting Novo Nordisk A/S 2021-03-09
NCT04161495 A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, BIVV001, in Patients With Severe Hemophilia A (XTEND-1) https://ClinicalTrials.gov/show/NCT04161495 Recruiting Sanofi 2021-05-31
NCT04135300 Gene Therapy for Chinese Hemophilia B https://ClinicalTrials.gov/show/NCT04135300 Recruiting Institute of Hematology & Blood Diseases Hospital 2021-06-30
NCT04133883 Impact on French Physician’s Haemophilia Treatment Management Decision Based on Systematic Joint Examination https://ClinicalTrials.gov/show/NCT04133883 Recruiting Swedish Orphan Biovitrum 2022-02-28
NCT04076306 What is the Feasibility of the ISTEP Exercise Test in Boys With Haemophilia https://ClinicalTrials.gov/show/NCT04076306 Completed Great Ormond Street Hospital for Children NHS Foundation Trust 2018-11-02
NCT04073498 The Safety and Tolerability of SerpinPC in Healthy Men and in Men With Severe Blood Disorders (Haemophilia A and B) https://ClinicalTrials.gov/show/NCT04073498 Recruiting ApcinteX Ltd 2021-04-30
NCT04072237 Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia https://ClinicalTrials.gov/show/NCT04072237 Active, not recruiting Catalyst Biosciences 2020-04-30
NCT04061109 Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A. https://ClinicalTrials.gov/show/NCT04061109 Recruiting Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2020-03-31
NCT04060836 Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A. https://ClinicalTrials.gov/show/NCT04060836 Recruiting Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2020-03-31
NCT04046848 Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT04046848 Active, not recruiting Octapharma 2021-09-30
NCT03974113 Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B https://ClinicalTrials.gov/show/NCT03974113 Recruiting Sanofi 2023-09-30
NCT03935334 Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors https://ClinicalTrials.gov/show/NCT03935334 Recruiting AryoGen Pharmed Co. 2020-06-30
NCT03915080 Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A https://ClinicalTrials.gov/show/NCT03915080 Recruiting Lund University 2020-12-31
NCT03914716 Imaging of Arthropathy in Boys With Hemophilia in China https://ClinicalTrials.gov/show/NCT03914716 Recruiting The Hospital for Sick Children 2020-06-30
NCT03861273 A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B https://ClinicalTrials.gov/show/NCT03861273 Recruiting Pfizer 2021-11-26
NCT03855696 A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients https://ClinicalTrials.gov/show/NCT03855696 Recruiting Green Cross Corporation 2019-10-31
NCT03855280 Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B https://ClinicalTrials.gov/show/NCT03855280 Recruiting Medexus Pharma, Inc. 2021-08-01
NCT03842605 Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia https://ClinicalTrials.gov/show/NCT03842605 Completed Oregon Health and Science University 2019-02-28
NCT03818763 Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A https://ClinicalTrials.gov/show/NCT03818763 Recruiting Medical College of Wisconsin 2023-05-01
NCT03815318 Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT03815318 Completed Sinocelltech Ltd. 2020-01-16
NCT03754790 Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX https://ClinicalTrials.gov/show/NCT03754790 Recruiting Sanofi 2026-01-31
NCT03734588 Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors https://ClinicalTrials.gov/show/NCT03734588 Active, not recruiting Spark Therapeutics 2020-05-31
NCT03700229 Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A https://ClinicalTrials.gov/show/NCT03700229 Recruiting Peking Union Medical College Hospital 2019-10-15
NCT03641703 A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy https://ClinicalTrials.gov/show/NCT03641703 Recruiting Freeline Therapeutics 2035-12-31
NCT03622476 Pharmacokinetic (PK)Research on Chinese Children of Hemophilia https://ClinicalTrials.gov/show/NCT03622476 Recruiting Beijing Children’s Hospital 2021-07-30
NCT03615053 Personalized Medicine for Canadians With Hemophilia https://ClinicalTrials.gov/show/NCT03615053 Recruiting McMaster University 2021-09-30
NCT03598725 Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China https://ClinicalTrials.gov/show/NCT03598725 Recruiting Beijing Children’s Hospital 2019-12-01
NCT03587116 Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%) https://ClinicalTrials.gov/show/NCT03587116 Recruiting Pfizer 2021-09-24
NCT03574922 The Effects of Core Stabilization Exercises in Addition to Balance Exercises in Adult Hemophilia Patients on Balance, Quality of Life, Lower Limb Muscle Strength and Functional Level https://ClinicalTrials.gov/show/NCT03574922 Completed Hacettepe University 2019-02-01
NCT03569891 HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients https://ClinicalTrials.gov/show/NCT03569891 Active, not recruiting UniQure Biopharma B.V. 2020-09-30
NCT03549871 A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis https://ClinicalTrials.gov/show/NCT03549871 Recruiting Sanofi 2022-03-31
NCT03529474 Psychology and Physiotherapy Approach of Chronic Pain in Patients With Hemophilia https://ClinicalTrials.gov/show/NCT03529474 Completed Instituto de Investigacion Sanitaria La Fe 2019-03-15
NCT03520712 Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 https://ClinicalTrials.gov/show/NCT03520712 Enrolling by invitation BioMarin Pharmaceutical 2025-06-30
NCT03507582 Virtual Reality for Hemophilia https://ClinicalTrials.gov/show/NCT03507582 Completed Nationwide Children’s Hospital 2016-12-28
NCT03489291 Dose Confirmation Trial of AAV5-hFIXco-Padua https://ClinicalTrials.gov/show/NCT03489291 Active, not recruiting UniQure Biopharma B.V. 2018-10-30
NCT03481946 A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia https://ClinicalTrials.gov/show/NCT03481946 Completed Bayer 2018-10-17
NCT03449342 Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period https://ClinicalTrials.gov/show/NCT03449342 Completed Novo Nordisk A/S 2019-03-25
NCT03417245 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors https://ClinicalTrials.gov/show/NCT03417245 Active, not recruiting Sanofi 2021-04-30
NCT03417102 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors https://ClinicalTrials.gov/show/NCT03417102 Active, not recruiting Sanofi 2020-12-31
NCT01238367 A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543 https://ClinicalTrials.gov/show/NCT01238367 Completed Novo Nordisk A/S 2011-10-31
NCT01233440 Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B https://ClinicalTrials.gov/show/NCT01233440 Completed CSL Behring 2011-07-31
NCT01233258 A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT01233258 Completed Bayer 2012-12-31
NCT01229007 Study of Biostate® in Children With Hemophilia A https://ClinicalTrials.gov/show/NCT01229007 Completed CSL Behring 2014-07-31
NCT01228669 Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B https://ClinicalTrials.gov/show/NCT01228669 Completed Novo Nordisk A/S 2012-09-10
NCT01205724 Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A https://ClinicalTrials.gov/show/NCT01205724 Completed Novo Nordisk A/S 2011-04-30
NCT01184820 Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration https://ClinicalTrials.gov/show/NCT01184820 Completed Bayer 2011-10-10
NCT01181128 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT01181128 Completed Bioverativ Therapeutics Inc. 2012-08-31
NCT01178294 Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A https://ClinicalTrials.gov/show/NCT01178294 Completed Shire 2013-07-01
NCT01174446 Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients https://ClinicalTrials.gov/show/NCT01174446 Completed Shire 2012-05-03
NCT01138501 Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A https://ClinicalTrials.gov/show/NCT01138501 Completed Novo Nordisk A/S 2011-11-30
NCT01128881 IMMUNINE Pre-Treatment Study https://ClinicalTrials.gov/show/NCT01128881 Completed Shire 2012-08-31
NCT01125813 Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT01125813 Completed Octapharma 2012-01-31
NCT01090206 Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia https://ClinicalTrials.gov/show/NCT01090206 Completed Virginia Commonwealth University 2013-03-31
NCT01085344 Canadian Hemophilia Prophylaxis Study https://ClinicalTrials.gov/show/NCT01085344 Completed The Hospital for Sick Children 2012-12-31
NCT01064284 Survey of Inhibitors in Plasma-Product Exposed Toddlers https://ClinicalTrials.gov/show/NCT01064284 Completed Fondazione Angelo Bianchi Bonomi 2015-05-31
NCT01051544 Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive https://ClinicalTrials.gov/show/NCT01051544 Active, not recruiting City of Hope Medical Center 2020-06-30
NCT01051076 Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) https://ClinicalTrials.gov/show/NCT01051076 Active, not recruiting City of Hope Medical Center 2020-06-30
NCT01029340 Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A https://ClinicalTrials.gov/show/NCT01029340 Completed Bayer 2012-06-30
NCT01027377 Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT01027377 Completed Bioverativ Therapeutics Inc. 2010-07-31
NCT01027364 Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B https://ClinicalTrials.gov/show/NCT01027364 Completed Bioverativ Therapeutics Inc. 2012-07-31
NCT00994929 Efficacy and Safety of IL-11 in DDAVP Unresponsive https://ClinicalTrials.gov/show/NCT00994929 Completed University of Pittsburgh 2012-04-30
NCT00989196 Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT00989196 Completed Octapharma 2011-10-31
NCT00984126 Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 https://ClinicalTrials.gov/show/NCT00984126 Completed Novo Nordisk A/S 2016-06-28
NCT00979238 Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B https://ClinicalTrials.gov/show/NCT00979238 Active, not recruiting St. Jude Children’s Research Hospital 2032-06-12
NCT00956345 Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B https://ClinicalTrials.gov/show/NCT00956345 Completed Novo Nordisk A/S 2010-07-31
NCT00952822 Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection https://ClinicalTrials.gov/show/NCT00952822 Completed Shire 2009-10-31
NCT00951873 A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers https://ClinicalTrials.gov/show/NCT00951873 Completed Novo Nordisk A/S 2010-04-30
NCT00951405 Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors https://ClinicalTrials.gov/show/NCT00951405 Completed Novo Nordisk A/S 2011-03-29
NCT00950170 Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting https://ClinicalTrials.gov/show/NCT00950170 Completed Pfizer 2016-11-24
NCT00927667 Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens https://ClinicalTrials.gov/show/NCT00927667 Completed Bayer 2010-12-31
NCT00922792 Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B https://ClinicalTrials.gov/show/NCT00922792 Completed Novo Nordisk A/S 2009-09-30
NCT00914459 Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients https://ClinicalTrials.gov/show/NCT00914459 Completed Pfizer 2016-03-31
NCT00879541 Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A https://ClinicalTrials.gov/show/NCT00879541 Completed CSL Behring 2010-10-31
NCT00916032 Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT00916032 Completed Shire 2010-04-30
NCT00868530 Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects https://ClinicalTrials.gov/show/NCT00868530 Completed Pfizer 2009-12-31
NCT00866606 Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects https://ClinicalTrials.gov/show/NCT00866606 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2009-12-31
NCT00851721 Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor https://ClinicalTrials.gov/show/NCT00851721 Completed Shire 2012-10-31
NCT00840086 Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects https://ClinicalTrials.gov/show/NCT00840086 Completed Novo Nordisk A/S 2011-09-30
NCT00839202 Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay https://ClinicalTrials.gov/show/NCT00839202 Completed Children’s Hospital Los Angeles 2008-09-30
NCT03009591 Fascial Therapy in Elbow Hemophilic Arthropathy https://ClinicalTrials.gov/show/NCT03009591 Completed Real Fundación Victoria Eugenia 2018-12-01
NCT02825706 Educational Physiotherapy in Haemophilia https://ClinicalTrials.gov/show/NCT02825706 Completed Real Fundación Victoria Eugenia 2012-10-31
NCT00837356 Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects https://ClinicalTrials.gov/show/NCT00837356 Completed Novo Nordisk A/S 2009-10-31
NCT04015492 Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII) https://ClinicalTrials.gov/show/NCT04015492 Completed Bayer 2019-10-25
NCT03947567 Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients. https://ClinicalTrials.gov/show/NCT03947567 Recruiting Sinocelltech Ltd. 2025-04-01
NCT01562457 Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State https://ClinicalTrials.gov/show/NCT01562457 Completed Novo Nordisk A/S 2006-04-30
NCT04085458 Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophila A (Post-marketing Investigation) https://ClinicalTrials.gov/show/NCT04085458 Recruiting Bayer 2022-08-31
NCT03938792 Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B https://ClinicalTrials.gov/show/NCT03938792 Recruiting Pfizer 2023-04-27
NCT02172950 An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT02172950 Active, not recruiting CSL Behring 2025-07-01
NCT02137850 Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A https://ClinicalTrials.gov/show/NCT02137850 Enrolling by invitation Novo Nordisk A/S 2021-11-13
NCT02053792 A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B https://ClinicalTrials.gov/show/NCT02053792 Active, not recruiting CSL Behring 2021-09-30
NCT03091751 Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B https://ClinicalTrials.gov/show/NCT03091751 Completed Grifols Biologicals, LLC 2009-10-31
NCT03528551 A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A https://ClinicalTrials.gov/show/NCT03528551 Active, not recruiting Novo Nordisk A/S 2020-12-03
NCT02256917 Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A https://ClinicalTrials.gov/show/NCT02256917 Completed Octapharma 2018-09-30
NCT01496274 A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B https://ClinicalTrials.gov/show/NCT01496274 Completed CSL Behring 2014-07-31
NCT02170402 China ADVATE PTP Study https://ClinicalTrials.gov/show/NCT02170402 Completed Shire 2016-05-31
NCT00768287 Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B https://ClinicalTrials.gov/show/NCT00768287 Completed Aptevo Therapeutics 2013-03-31
NCT00749476 Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX https://ClinicalTrials.gov/show/NCT00749476 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2009-01-31
NCT00717626 Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT00717626 Completed The Hospital for Sick Children 2011-04-30
NCT00716716 Phase I/IIa Study of FIXFc in Hemophilia B Patients https://ClinicalTrials.gov/show/NCT00716716 Completed Bioverativ Therapeutics Inc. 2009-10-31
NCT00707772 Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT00707772 Completed Baqiyatallah Medical Sciences University 2009-09-30
NCT00666406 Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT00666406 Completed Shire 2009-08-31
NCT00640289 Clinical Trial of Factor XIII (FXIII) Concentrate https://ClinicalTrials.gov/show/NCT00640289 Completed Children’s Hospital of Orange County 2011-12-31
NCT00638001 Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy https://ClinicalTrials.gov/show/NCT00638001 Completed Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2012-03-31
NCT00632814 Russian Kogenate Pediatric Study https://ClinicalTrials.gov/show/NCT00632814 Completed Bayer 2009-09-30
NCT00629837 Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 https://ClinicalTrials.gov/show/NCT00629837 Completed Bayer NA
NCT00623480 Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment https://ClinicalTrials.gov/show/NCT00623480 Completed Bayer 2011-09-30
NCT00606060 BAY14-2222 Continuous Infusion in Surgeries https://ClinicalTrials.gov/show/NCT00606060 Completed Bayer NA
NCT00586521 BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) https://ClinicalTrials.gov/show/NCT00586521 Completed Bayer 2008-03-31
NCT00581126 Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B https://ClinicalTrials.gov/show/NCT00581126 Completed Wyeth is now a wholly owned subsidiary of Pfizer NA
NCT00571584 High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors https://ClinicalTrials.gov/show/NCT00571584 Completed Novo Nordisk A/S 2004-03-31
NCT00543439 Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII https://ClinicalTrials.gov/show/NCT00543439 Completed Pfizer 2018-04-30
NCT00486278 Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds https://ClinicalTrials.gov/show/NCT00486278 Completed Novo Nordisk A/S 2010-06-30
NCT00375323 Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation https://ClinicalTrials.gov/show/NCT00375323 Completed Medical University of Vienna NA
NCT00364182 Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B https://ClinicalTrials.gov/show/NCT00364182 Completed Pfizer 2010-10-31
NCT00357656 Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery https://ClinicalTrials.gov/show/NCT00357656 Completed Shire 2015-10-01
NCT00323856 Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT00323856 Active, not recruiting Grifols Biologicals, LLC 2018-12-31
NCT00289536 Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A https://ClinicalTrials.gov/show/NCT00289536 Completed Shire 2007-04-30
NCT00284193 Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII https://ClinicalTrials.gov/show/NCT00284193 Completed Sheba Medical Center 2008-11-30
NCT00279578 Clot Formation and Clot Stability in Patients With Severe Haemophilia A https://ClinicalTrials.gov/show/NCT00279578 Completed University of Aarhus NA
NCT00245297 Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes. https://ClinicalTrials.gov/show/NCT00245297 Completed Recoly N.V. NA
NCT00245245 Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII https://ClinicalTrials.gov/show/NCT00245245 Completed Octagen Corporation NA
NCT00243659 Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery https://ClinicalTrials.gov/show/NCT00243659 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2008-06-30
NCT00243386 Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A https://ClinicalTrials.gov/show/NCT00243386 Completed Shire 2010-06-30
NCT00221195 Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors https://ClinicalTrials.gov/show/NCT00221195 Completed Tulane University 2009-12-31
NCT00212459 The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs https://ClinicalTrials.gov/show/NCT00212459 Completed New York Presbyterian Hospital 2006-02-28
NCT00189982 Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101 https://ClinicalTrials.gov/show/NCT00189982 Completed Shire NA
NCT00168090 Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) https://ClinicalTrials.gov/show/NCT00168090 Completed CSL Behring NA
NCT00166309 The FEIBA NovoSeven Comparative Study https://ClinicalTrials.gov/show/NCT00166309 Completed Skane University Hospital NA
NCT00162019 Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients https://ClinicalTrials.gov/show/NCT00162019 Completed Shire 2004-08-31
NCT00157157 Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients https://ClinicalTrials.gov/show/NCT00157157 Completed Shire 2009-09-11
NCT00157105 Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery https://ClinicalTrials.gov/show/NCT00157105 Completed Shire NA
NCT00157053 Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901 https://ClinicalTrials.gov/show/NCT00157053 Completed Shire NA
NCT00157040 Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A https://ClinicalTrials.gov/show/NCT00157040 Completed Shire 2005-01-31
NCT00141843 Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A https://ClinicalTrials.gov/show/NCT00141843 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2006-11-30
NCT00139828 Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX) https://ClinicalTrials.gov/show/NCT00139828 Completed Sanquin Plasma Products BV NA
NCT00108797 Trial of NovoSeven® in Haemophilia - Joint Bleeds https://ClinicalTrials.gov/show/NCT00108797 Completed Novo Nordisk A/S 2006-02-28
NCT00108758 Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia https://ClinicalTrials.gov/show/NCT00108758 Completed Novo Nordisk A/S 2005-11-30
NCT00093210 Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B https://ClinicalTrials.gov/show/NCT00093210 Completed Wyeth is now a wholly owned subsidiary of Pfizer NA
NCT00093171 Study Evaluating rFIX; BeneFIX® in Hemophilia B https://ClinicalTrials.gov/show/NCT00093171 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2005-05-31
NCT00092976 Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery https://ClinicalTrials.gov/show/NCT00092976 Completed Wyeth is now a wholly owned subsidiary of Pfizer NA
NCT00038935 Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A https://ClinicalTrials.gov/show/NCT00038935 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2003-02-28
NCT00038909 Study Evaluating ReFacto in Hemophilia A https://ClinicalTrials.gov/show/NCT00038909 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2001-05-31
NCT00037557 Study Evaluating rFIX; BeneFIX in Severe Hemophilia B https://ClinicalTrials.gov/show/NCT00037557 Completed Wyeth is now a wholly owned subsidiary of Pfizer NA
NCT00037544 Study Evaluating ReFacto AF in Severe Hemophilia A https://ClinicalTrials.gov/show/NCT00037544 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2004-08-31
NCT00331006 Rituximab to Treat Severe Hemophilia A https://ClinicalTrials.gov/show/NCT00331006 Completed HealthCore-NERI 2010-11-30
NCT00002386 Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia https://ClinicalTrials.gov/show/NCT00002386 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002276 The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia https://ClinicalTrials.gov/show/NCT00002276 Completed NIH AIDS Clinical Trials Information Service NA
NCT00000705 Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia https://ClinicalTrials.gov/show/NCT00000705 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000582 Cooperative Study of Factor VIII Inhibitors https://ClinicalTrials.gov/show/NCT00000582 Completed National Heart, Lung, and Blood Institute (NHLBI) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03405337 Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies https://ClinicalTrials.gov/show/NCT03405337 Completed Bayer 2018-06-13
NCT03034044 Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe https://ClinicalTrials.gov/show/NCT03034044 Completed Pfizer 2018-01-17
NCT03824522 A Post Marketing Surveillance Study for ADYNOVATE in South Korea https://ClinicalTrials.gov/show/NCT03824522 Recruiting Shire 2023-12-31
NCT03358836 Joint Health Study https://ClinicalTrials.gov/show/NCT03358836 Active, not recruiting Bloodworks 2027-12-31
NCT03344003 Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq https://ClinicalTrials.gov/show/NCT03344003 Recruiting Octapharma 2027-12-31
NCT03313531 Evaluation of a Standardized Protocol for Thrombin Generation Assay https://ClinicalTrials.gov/show/NCT03313531 Completed Lund University 2019-01-28
NCT03287999 Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B https://ClinicalTrials.gov/show/NCT03287999 Recruiting Royal Free Hospital NHS Foundation Trust 2019-10-02
NCT03276130 Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B https://ClinicalTrials.gov/show/NCT03276130 Recruiting Swedish Orphan Biovitrum 2019-12-31
NCT03264014 Combining Registry Data in Haemophilia: TARGET H https://ClinicalTrials.gov/show/NCT03264014 Completed University of Pretoria 2015-09-30
NCT03199794 Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice https://ClinicalTrials.gov/show/NCT03199794 Recruiting Shire 2021-05-31
NCT03185897 Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia https://ClinicalTrials.gov/show/NCT03185897 Active, not recruiting Shire 2022-04-30
NCT03179748 Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients https://ClinicalTrials.gov/show/NCT03179748 Enrolling by invitation Novo Nordisk A/S 2021-06-28
NCT03169972 ADYNOVATE Drug Use-Results Survey https://ClinicalTrials.gov/show/NCT03169972 Recruiting Shire 2021-12-31
NCT00835068 Post Marketing Observational Study of Reformulated BeneFIX https://ClinicalTrials.gov/show/NCT00835068 Completed Pfizer 2013-10-31
NCT03054389 Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews https://ClinicalTrials.gov/show/NCT03054389 Completed Shire 2017-06-06
NCT03006965 Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT® https://ClinicalTrials.gov/show/NCT03006965 Recruiting Spanish Society of Thrombosis and Haemostasis 2020-05-22
NCT02976753 Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products https://ClinicalTrials.gov/show/NCT02976753 Active, not recruiting Swedish Orphan Biovitrum 2021-10-31
NCT02971930 Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A https://ClinicalTrials.gov/show/NCT02971930 Completed Bayer 2017-11-26
NCT02962765 Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ https://ClinicalTrials.gov/show/NCT02962765 Active, not recruiting Octapharma 2020-07-31
NCT02941783 Drug Use Investigation of Kovaltry in Hemophilia A Patients https://ClinicalTrials.gov/show/NCT02941783 Recruiting Bayer 2021-05-31
NCT02938156 UK - EHL Outcomes Registry https://ClinicalTrials.gov/show/NCT02938156 Recruiting Royal Free Hospital NHS Foundation Trust 2019-10-31
NCT02922231 Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea https://ClinicalTrials.gov/show/NCT02922231 Completed Shire 2019-04-04
NCT02870114 National Survey of People With Haemophilia in Portugal https://ClinicalTrials.gov/show/NCT02870114 Completed University of Minho 2017-05-22
NCT02807753 The Hemophilia Ultrasound Project https://ClinicalTrials.gov/show/NCT02807753 Recruiting University of Miami 2021-07-31
NCT02796222 Factor Product Utilization and Health Outcomes in Patients With Hemophilia https://ClinicalTrials.gov/show/NCT02796222 Recruiting University of British Columbia 2019-12-31
NCT02750085 Evaluation of a Simple Pharmacokinetic Tool (myPKFiTâ„¢) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia https://ClinicalTrials.gov/show/NCT02750085 Active, not recruiting The Hospital for Sick Children 2019-01-31
NCT02740413 Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study https://ClinicalTrials.gov/show/NCT02740413 Completed Pfizer 2017-12-31
NCT02674997 GAS-Hem Feasibility Study https://ClinicalTrials.gov/show/NCT02674997 Completed Shire 2016-11-02
NCT02634918 Ultrasonography in Hemophilic Joint Disease and Serum Markers https://ClinicalTrials.gov/show/NCT02634918 Completed Northwell Health 2019-08-31
NCT02634723 Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A https://ClinicalTrials.gov/show/NCT02634723 Completed Shire 2016-06-30
NCT02610127 Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A https://ClinicalTrials.gov/show/NCT02610127 Completed Shire 2019-06-07
NCT02585635 Risk Models to Optimise Prophylaxis Schedules in Children With Haemophilia https://ClinicalTrials.gov/show/NCT02585635 Completed Neuroscience Research Australia 2018-02-01
NCT02581969 Extension at 10 Years of the: “Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A.” https://ClinicalTrials.gov/show/NCT02581969 Completed Bayer 2017-03-16
NCT04055051 ATHN 11: Liver Transplantation Outcomes Study https://ClinicalTrials.gov/show/NCT04055051 Enrolling by invitation American Thrombosis and Hemostasis Network 2022-06-30
NCT02830477 Study Evaluating “Real World” Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis https://ClinicalTrials.gov/show/NCT02830477 Active, not recruiting Bayer 2020-12-01
NCT02035384 Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A https://ClinicalTrials.gov/show/NCT02035384 Completed Novo Nordisk A/S 2020-01-15
NCT02546622 ATHN 2: Factor Switching Study https://ClinicalTrials.gov/show/NCT02546622 Active, not recruiting American Thrombosis and Hemostasis Network 2020-06-30
NCT02540187 Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients https://ClinicalTrials.gov/show/NCT02540187 Completed Centre Hospitalier Universitaire de Saint Etienne 2016-02-29
NCT02476942 A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment https://ClinicalTrials.gov/show/NCT02476942 Completed Hoffmann-La Roche 2017-03-31
NCT02396862 Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment https://ClinicalTrials.gov/show/NCT02396862 Completed Bayer 2018-01-17
NCT02300519 Thrombin Generation Numerical Models Validation in Haemophilic Case https://ClinicalTrials.gov/show/NCT02300519 Completed Centre Hospitalier Universitaire de Saint Etienne 2015-07-31
NCT02263066 Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFâ…§ Contained Regular Prophylaxis https://ClinicalTrials.gov/show/NCT02263066 Completed Bayer 2015-07-31
NCT02241694 To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives https://ClinicalTrials.gov/show/NCT02241694 Completed Novo Nordisk A/S 2015-07-31
NCT02225483 Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function https://ClinicalTrials.gov/show/NCT02225483 Completed CancerCare Manitoba 2015-12-31
NCT02207894 A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI https://ClinicalTrials.gov/show/NCT02207894 Recruiting Haemophilia Centre Rhine Main 2026-12-31
NCT02207218 To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan https://ClinicalTrials.gov/show/NCT02207218 Active, not recruiting Novo Nordisk A/S 2021-02-04
NCT02198430 Multidisciplinary Evaluation of Patients With Hemophilia https://ClinicalTrials.gov/show/NCT02198430 Completed Universidad de Murcia 2015-11-30
NCT02190149 Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS https://ClinicalTrials.gov/show/NCT02190149 Completed Shire 2016-03-31
NCT02093741 ADVATE 2 mL Post-Authorization Safety Surveillance (PASS) https://ClinicalTrials.gov/show/NCT02093741 Completed Shire 2016-01-20
NCT02093065 Platelet Function in Patients With Hemophilia A https://ClinicalTrials.gov/show/NCT02093065 Enrolling by invitation Boston Children’s Hospital 2018-06-30
NCT02078427 ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) https://ClinicalTrials.gov/show/NCT02078427 Active, not recruiting Shire 2025-01-15
NCT01285089 Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia https://ClinicalTrials.gov/show/NCT01285089 Completed Novo Nordisk A/S 2013-10-31
NCT03360149 Health Practice of Hemophilia Patiente Care During Pregnancy, Delivery and Newborn Children https://ClinicalTrials.gov/show/NCT03360149 Completed University Hospital, Brest 2016-10-05
NCT02049099 A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care https://ClinicalTrials.gov/show/NCT02049099 Completed Swedish Orphan Biovitrum 2015-09-30
NCT01988532 Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia https://ClinicalTrials.gov/show/NCT01988532 Completed Novo Nordisk A/S 2014-10-31
NCT01959919 Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO https://ClinicalTrials.gov/show/NCT01959919 Completed Pfizer 2016-12-12
NCT01959555 Project to Update the Study of Congenital Haemophilia in Spain https://ClinicalTrials.gov/show/NCT01959555 Completed Novo Nordisk A/S 2014-12-31
NCT01830712 A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors https://ClinicalTrials.gov/show/NCT01830712 Completed Novo Nordisk A/S 2011-08-31
NCT01817868 Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients https://ClinicalTrials.gov/show/NCT01817868 Completed Bayer 2018-07-16
NCT01790828 Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A https://ClinicalTrials.gov/show/NCT01790828 Completed Pfizer 2014-08-31
NCT01652027 Hemophilia Inhibitor Previously Untreated Patient Study https://ClinicalTrials.gov/show/NCT01652027 Active, not recruiting The University of Texas Health Science Center, Houston 2019-12-31
NCT01589848 Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador https://ClinicalTrials.gov/show/NCT01589848 Completed Universidad del Azuay 2013-06-30
NCT01586936 Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors https://ClinicalTrials.gov/show/NCT01586936 Completed Novo Nordisk A/S 2010-03-09
NCT01579968 Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery https://ClinicalTrials.gov/show/NCT01579968 Completed Novo Nordisk A/S 2010-03-09
NCT01579955 Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice https://ClinicalTrials.gov/show/NCT01579955 Completed Novo Nordisk A/S 2010-03-09
NCT01571934 Inhibitor Development in Patients With Hemophilia A Undergoing Surgery https://ClinicalTrials.gov/show/NCT01571934 Completed Emory University 2016-02-29
NCT01510418 Socialization of Adult Men With Congenital Hemophilia A or B https://ClinicalTrials.gov/show/NCT01510418 Completed Dana-Farber Cancer Institute 2013-05-31
NCT01503567 Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries https://ClinicalTrials.gov/show/NCT01503567 Completed Novo Nordisk A/S 2012-09-30
NCT01436825 Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients https://ClinicalTrials.gov/show/NCT01436825 Completed Bayer 2014-06-30
NCT01431326 Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care https://ClinicalTrials.gov/show/NCT01431326 Completed Duke University 2019-11-30
NCT01318707 Biomarkers Serum Collection Methodology Pilot Study https://ClinicalTrials.gov/show/NCT01318707 Completed Georgetown University 2011-05-31
NCT01386268 Kogenate FS Regulatory Post-Marketing Surveillance https://ClinicalTrials.gov/show/NCT01386268 Completed Bayer 2013-01-31
NCT01322620 Survey Evaluating the Psychosocial Effects of Living With Haemophilia https://ClinicalTrials.gov/show/NCT01322620 Completed Novo Nordisk A/S 2012-02-29
NCT04293523 A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health https://ClinicalTrials.gov/show/NCT04293523 Recruiting Swedish Orphan Biovitrum 2026-09-30
NCT04206033 Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins https://ClinicalTrials.gov/show/NCT04206033 Recruiting Nantes University Hospital 2020-12-31
NCT04181697 HemFitBit, an Observational Study of Physical Activity in People With Moderate and Severe Haemophilia A https://ClinicalTrials.gov/show/NCT04181697 Enrolling by invitation Oslo University Hospital 2020-06-30
NCT04165135 An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment https://ClinicalTrials.gov/show/NCT04165135 Recruiting Hoffmann-La Roche 2020-12-31
NCT04131036 Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A https://ClinicalTrials.gov/show/NCT04131036 Recruiting Bloodworks 2023-08-31
NCT04023019 Treatment of Hemophilia A Patients With FVIII Inhibitors https://ClinicalTrials.gov/show/NCT04023019 Recruiting Emory University 2028-12-31
NCT03951103 rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A https://ClinicalTrials.gov/show/NCT03951103 Recruiting Swedish Orphan Biovitrum 2023-11-06
NCT03932201 Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A https://ClinicalTrials.gov/show/NCT03932201 Recruiting Bayer 2025-06-30
NCT03876301 Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants https://ClinicalTrials.gov/show/NCT03876301 Active, not recruiting Spark Therapeutics 2020-07-31
NCT03875547 Post-marketing Surveillance (Use Result Surveillance) With Refixia® https://ClinicalTrials.gov/show/NCT03875547 Enrolling by invitation Novo Nordisk A/S 2025-09-30
NCT03818529 ATHN 8: PUPs Matter Study https://ClinicalTrials.gov/show/NCT03818529 Recruiting American Thrombosis and Hemostasis Network 2023-03-31
NCT03747653 A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection https://ClinicalTrials.gov/show/NCT03747653 Active, not recruiting Kaifeng Pharmaceutical (Group) Co., Ltd. 2020-05-31
NCT03695978 Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients https://ClinicalTrials.gov/show/NCT03695978 Recruiting Octapharma 2022-06-30
NCT03655340 A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France https://ClinicalTrials.gov/show/NCT03655340 Active, not recruiting Swedish Orphan Biovitrum 2021-09-30
NCT03623295 The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B https://ClinicalTrials.gov/show/NCT03623295 Recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 2020-04-01
NCT03596814 MOTHIF II : THERAPEUTIC MANAGEMENT AND USE OF CLOTTING FACTORS IN HEMOPHILIA A & B IN FRANCE II https://ClinicalTrials.gov/show/NCT03596814 Completed Nantes University Hospital 2019-12-31
NCT03541811 Gait Examination in Patients With Hemophilia in Austria https://ClinicalTrials.gov/show/NCT03541811 Completed FH Campus Wien, University of Applied Sciences 2019-07-01
NCT03432520 Long-Term Safety and Efficacy of SPK-8011 in Males With Hemophilia A https://ClinicalTrials.gov/show/NCT03432520 Enrolling by invitation Spark Therapeutics 2022-12-31
NCT03430154 Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE) https://ClinicalTrials.gov/show/NCT03430154 Completed Novo Nordisk A/S 2018-04-29
NCT01234545 Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors https://ClinicalTrials.gov/show/NCT01234545 Completed Novo Nordisk A/S 2012-04-30
NCT01220141 Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B https://ClinicalTrials.gov/show/NCT01220141 Completed Novo Nordisk A/S 2015-03-31
NCT01159587 Prophylaxis Versus On-demand Therapy Through Economic Report https://ClinicalTrials.gov/show/NCT01159587 Completed Bayer 2010-12-31
NCT01053715 Quality of Life Study of Helixate NexGen https://ClinicalTrials.gov/show/NCT01053715 Completed CSL Behring 2015-01-31
NCT01034904 Health Related Quality of Life of Youth and Young Adults With Hemophilia A https://ClinicalTrials.gov/show/NCT01034904 Completed CSL Behring 2013-07-31
NCT01029808 Bleeding Symptoms of Carriers of Hemophilia A and B https://ClinicalTrials.gov/show/NCT01029808 Completed Sahlgrenska University Hospital, Sweden 2011-07-31
NCT01000844 Joint Outcome Study Continuation for Children With Severe Factor VIII Deficiency https://ClinicalTrials.gov/show/NCT01000844 Completed University of Colorado, Denver 2017-10-31
NCT00972296 Comparison of Two Types of Ankle Braces in the Management of Ankle Pain in Hemophilia https://ClinicalTrials.gov/show/NCT00972296 Completed Oregon Health and Science University 2011-05-31
NCT00969319 Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America https://ClinicalTrials.gov/show/NCT00969319 Completed Bayer 2013-02-28
NCT00936845 Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study https://ClinicalTrials.gov/show/NCT00936845 Completed Weill Medical College of Cornell University 2010-01-31
NCT00936312 Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study https://ClinicalTrials.gov/show/NCT00936312 Completed Weill Medical College of Cornell University 2011-08-31
NCT00932555 EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan https://ClinicalTrials.gov/show/NCT00932555 Completed Bayer NA
NCT00927992 Study Evaluating Liver Transplantation in Haemophilia Patients in Spain https://ClinicalTrials.gov/show/NCT00927992 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2010-06-30
NCT00922597 Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery https://ClinicalTrials.gov/show/NCT00922597 Completed Bayer NA
NCT00895037 Study Evaluating Pharmacovigilance Of Refacto AF https://ClinicalTrials.gov/show/NCT00895037 Completed Pfizer 2016-10-19
NCT00882778 PROPACT: Retrospective Prophylaxis Patient Case Collection https://ClinicalTrials.gov/show/NCT00882778 Completed Novo Nordisk A/S 2010-05-31
NCT00874926 EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS https://ClinicalTrials.gov/show/NCT00874926 Completed Bayer 2012-11-30
NCT00864552 International PMS Study - KOGENATE Bayer https://ClinicalTrials.gov/show/NCT00864552 Completed Bayer NA
NCT00853086 Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database https://ClinicalTrials.gov/show/NCT00853086 Completed Novo Nordisk A/S 2011-06-30
NCT03901755 An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B https://ClinicalTrials.gov/show/NCT03901755 Recruiting Swedish Orphan Biovitrum 2023-03-31
NCT03660774 A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia https://ClinicalTrials.gov/show/NCT03660774 Completed Novo Nordisk A/S 2019-10-11
NCT03533504 Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability https://ClinicalTrials.gov/show/NCT03533504 Enrolling by invitation McMaster University 2024-06-30
NCT03055611 A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B https://ClinicalTrials.gov/show/NCT03055611 Active, not recruiting Swedish Orphan Biovitrum 2022-04-30
NCT02568202 Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) https://ClinicalTrials.gov/show/NCT02568202 Completed Novo Nordisk A/S 2015-11-30
NCT01217255 Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World https://ClinicalTrials.gov/show/NCT01217255 Completed The Hospital for Sick Children 2013-10-31
NCT00824798 Gait Evaluation in Haemophiliac Patients https://ClinicalTrials.gov/show/NCT00824798 Completed Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2011-01-31
NCT03603275 Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry https://ClinicalTrials.gov/show/NCT03603275 Recruiting Bayer 2021-12-31
NCT02971969 Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B https://ClinicalTrials.gov/show/NCT02971969 Active, not recruiting Ultragenyx Pharmaceutical Inc 2022-02-18
NCT02911233 Evaluation of Clot Stability Induced by Solulin: Evaluation of New Solulin Mutants Lacking Protein C Activation Capacity https://ClinicalTrials.gov/show/NCT02911233 Completed University Hospital, Caen 2015-09-30
NCT03745924 A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN https://ClinicalTrials.gov/show/NCT03745924 Enrolling by invitation Novo Nordisk A/S 2027-12-15
NCT03741881 A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorerâ„¢6) https://ClinicalTrials.gov/show/NCT03741881 Enrolling by invitation Novo Nordisk A/S 2021-03-17
NCT02319070 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece https://ClinicalTrials.gov/show/NCT02319070 Completed Bayer 2017-05-28
NCT03157154 Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies https://ClinicalTrials.gov/show/NCT03157154 Completed Nantes University Hospital 2017-07-30
NCT01232634 Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles https://ClinicalTrials.gov/show/NCT01232634 Completed The Hospital for Sick Children 2013-11-30
NCT00782470 Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A https://ClinicalTrials.gov/show/NCT00782470 Completed Bayer 2010-11-30
NCT00710619 Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX https://ClinicalTrials.gov/show/NCT00710619 Completed Novo Nordisk A/S 2009-07-31
NCT00703911 Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors https://ClinicalTrials.gov/show/NCT00703911 Completed Novo Nordisk A/S 2010-07-31
NCT00697320 Observational Study on the Efficacy and Safety of NovoSeven® During “Real-life” Usage in Germany https://ClinicalTrials.gov/show/NCT00697320 Completed Novo Nordisk A/S 2010-12-31
NCT00581438 Study Evaluating Approach to Treatment of Haemophilia A and B in Spain https://ClinicalTrials.gov/show/NCT00581438 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2007-12-31
NCT00515710 LTFU for Gene Transfer Subjects With Hemophilia B https://ClinicalTrials.gov/show/NCT00515710 Completed Spark Therapeutics 2017-12-31
NCT00484185 Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B https://ClinicalTrials.gov/show/NCT00484185 Completed Pfizer 2012-06-30
NCT00344435 Genetic Susceptibility to Factor VIII Inhibitors https://ClinicalTrials.gov/show/NCT00344435 Completed National Institutes of Health Clinical Center (CC) NA
NCT00341705 The Second Multicenter Hemophilia Cohort Study https://ClinicalTrials.gov/show/NCT00341705 Completed National Institutes of Health Clinical Center (CC) NA
NCT00244114 Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients https://ClinicalTrials.gov/show/NCT00244114 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2009-12-31
NCT00231751 The Malmö International Brother Study (MIBS) https://ClinicalTrials.gov/show/NCT00231751 Completed Skane University Hospital NA
NCT00214734 ADVATE Post Authorization Safety Surveillance https://ClinicalTrials.gov/show/NCT00214734 Completed Shire NA
NCT00213473 Prospective Clinical and Biological Follow-up of Acquired Haemophilia : SACHA Study https://ClinicalTrials.gov/show/NCT00213473 Completed University Hospital, Rouen NA
NCT00207597 Joint Outcome Study https://ClinicalTrials.gov/show/NCT00207597 Completed Centers for Disease Control and Prevention NA
NCT00195442 Study Evaluating Refacto For Pharmacovigilance https://ClinicalTrials.gov/show/NCT00195442 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2010-01-31
NCT00195221 Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B https://ClinicalTrials.gov/show/NCT00195221 Completed Wyeth is now a wholly owned subsidiary of Pfizer NA
NCT00178607 Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia https://ClinicalTrials.gov/show/NCT00178607 Completed The University of Texas Health Science Center, Houston 2015-10-31
NCT00167973 Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use https://ClinicalTrials.gov/show/NCT00167973 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2009-06-30
NCT00166387 Hemophilia Inhibitor Genetics Study (HIGS) https://ClinicalTrials.gov/show/NCT00166387 Completed Skane University Hospital 2013-12-31
NCT00798499 A Feasibility Study to Collect Data in Patients With Haemophilia https://ClinicalTrials.gov/show/NCT00798499 Completed AstraZeneca NA
NCT00007371 Hepatitis C in Clinically Discordant Hemophilic Siblings https://ClinicalTrials.gov/show/NCT00007371 Completed University of North Carolina, Chapel Hill 2004-08-31
NCT00005518 Epidemiology and Immunology of Hemophilia A Inhibitors https://ClinicalTrials.gov/show/NCT00005518 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005309 Prospective Study of HIV Infection in Hemophiliacs https://ClinicalTrials.gov/show/NCT00005309 Completed Bloodworks 1995-03-31
NCT00005305 Hepatitis Delta Infections in Hemophiliacs https://ClinicalTrials.gov/show/NCT00005305 Completed University of North Carolina, Chapel Hill 1991-09-30
NCT00005304 Delta Hepatitis and Liver Disease in Hemophiliacs https://ClinicalTrials.gov/show/NCT00005304 Completed Baylor College of Medicine NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02912143 German Pediatric Hemophilia Research Database https://ClinicalTrials.gov/show/NCT02912143 Recruiting Ludwig-Maximilians - University of Munich 2022-01-01
NCT02512250 Swiss Hemophilia Registry https://ClinicalTrials.gov/show/NCT02512250 Recruiting Swiss Hemophilia Network 2025-12-31
NCT02453542 Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors https://ClinicalTrials.gov/show/NCT02453542 Recruiting Karolinska Institutet 2025-06-30
NCT02279199 Motor Proficiency of People With Bleeding Disorders Using the BOT-2 (TM) https://ClinicalTrials.gov/show/NCT02279199 Active, not recruiting Oregon Health and Science University 2022-01-31
NCT02199717 An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia https://ClinicalTrials.gov/show/NCT02199717 Completed The Hospital for Sick Children 2014-07-31
NCT02165462 Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy https://ClinicalTrials.gov/show/NCT02165462 Completed Universidad Católica San Antonio de Murcia 2015-10-31
NCT04406519 Evaluation of Static Postural Balance in Children With Hemophilia and Its Relationship With Joint Health https://ClinicalTrials.gov/show/NCT04406519 Completed Necmettin Erbakan University 2018-07-01
NCT03834727 Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders https://ClinicalTrials.gov/show/NCT03834727 Enrolling by invitation Oregon Health and Science University 2021-09-04
NCT03619863 ATHN 7: Hemophilia Natural History Study https://ClinicalTrials.gov/show/NCT03619863 Recruiting American Thrombosis and Hemostasis Network 2023-09-30
NCT02776826 World Bleeding Disorders Registry Pilot Study https://ClinicalTrials.gov/show/NCT02776826 Completed World Federation of Hemophilia 2016-12-31
NCT02253693 Exploratory Pilot Study of Physical Activity Monitoring in Adult Patients With Haemophilia A by Means of Accelerometry https://ClinicalTrials.gov/show/NCT02253693 Completed University of Valencia 2017-01-31